Comparing imaging methods for multiple myeloma assessment
Whole Body DWI Sequences As Compared with Standard FDG PET/CT in Patients with Simptomatic Multiple Myeloma
IRCCS Azienda Ospedaliero-Universitaria di Bologna · NCT06659276
This study is testing which imaging method, FDG PET/CT or whole body DWI MRI, works better for checking how well treatment is working in people with symptomatic multiple myeloma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 83 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna (other) |
| Locations | 1 site (Bologna) |
| Trial ID | NCT06659276 on ClinicalTrials.gov |
What this trial studies
This study evaluates the effectiveness of two imaging techniques, FDG PET/CT and whole body DWI MRI, in patients with symptomatic multiple myeloma. It aims to compare the positivity rates of both methods during the staging phase and at the end of therapy. The study will conduct an interim analysis followed by a final prognostic analysis to determine which imaging method provides better concordance in assessing the disease. Patients will be monitored for their responses to these imaging techniques throughout the study.
Who should consider this trial
Good fit: Ideal candidates include patients with symptomatic multiple myeloma who are in the staging or diagnostic phase.
Not a fit: Patients with other neoplastic diseases, those under 18, or individuals with contraindications for MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve the accuracy of staging and therapy assessment in patients with multiple myeloma.
How similar studies have performed: Other studies have shown promising results in using imaging techniques for cancer assessment, but this specific comparison is novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * • Patients with symptomatic myeloma in the staging phase or with suspected symptomatic myeloma in the diagnostic phase * Patients who have signed the informed consent form Exclusion Criteria: * Patients simultaneously affected by other neoplastic diseases or with a history of other neoplasms in the previous 5 years * Age \< 18 years * Women who are breastfeeding or pregnant * Patients with metal implants or devices that constitute an absolute contraindication for MRI * Patients with severe claustrophobia * Patients with bone pain that prevents prolonged maintenance of the supine position
Where this trial is running
Bologna
- Policlinico S.Orsola Malpighi — Bologna, Italy (RECRUITING)
Study contacts
- Study coordinator: CRISTINA NANNI, MD
- Email: cristina.nanni@aosp.bo.it
- Phone: +390512143182
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Multiple Myeloma, multiple myeloma, staging, therapy assessment, DWI, FDG PET CT